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A preclinical study was performed to determine if the extract from Phyllanthus niruri (PN) plays a protective role against liver cir-
rhosis induced by thioacetamide (TAA) in rats. Initially, acute toxicity was tested and the results showed that the extract was benign
when applied to healthy rats. Next, the therapeutic eﬀect of the extract was investigated using five groups of rats: control, TAA,
silymarin, and PN high dose and low dose groups. Significant diﬀerences were observed between the TAA group and the other
groups regarding body and liver weights, liver biochemical parameters, total antioxidant capacity, lipid peroxidation, and oxidative
stress enzyme levels. Gross visualization indicated coarse granules on the surface of the hepatotoxic rats’ livers, in contrast to the
smoother surface in the livers of the silymarin and PN-treated rats. Histopathological analysis revealed necrosis, lymphocytes infil-
tration in the centrilobular region, and fibrous connective tissue proliferation in the livers of the hepatotoxic rats. But, the livers of
the treated rats had comparativelyminimal inflammation and normal lobular architecture. Silymarin and PN treatments eﬀectively
restored these measurements closer to their normal levels. Progression of liver cirrhosis induced by TAA in rats can be intervened
using the PN extract and these eﬀects are comparable to those of silymarin.
1. Introduction
Herbal products have long been used in traditional folk
medicine to maintain health or to provide remedies for var-
ious human diseases [1]. Liver disorders, including liver cir-
rhosis, benefit from therapeutic strategies employing com-
pounds extracted from plants and herbs [2]. Phyllanthus nir-
uri (PN) is one of the herbal plants from the family of
Euphorbiaceae and the extract from this plant was widely
used in the preparation of various ayurvedic formulations
[3]. The analysis of the extract revealed several bioactive
molecules and chemical agents including phyllanthin, hypo-
phyllanthin, phyltetralin, niranthin, nirtetralin, hinokinin
and isolintetralin [4, 5]. Which are lignans belongs to the
polyphenols group of compounds with well known antiox-
idant properties [6]. Application of the extract exhibited
antiulcer, antitumor and anticarcinogenic, hypolipidemic,
antiviral, and antioxidant eﬀects. Past studies included the
extract in a multiherbal preparation to treat liver ailments
[7]. More recent explorations on the role of the extract has
confirmed that it possesses potent protective eﬀects against
viral hepatitis and toxicity caused by diﬀerent drugs or envi-
ronmental toxicants [8].
In this study, the previously implicated hepatoprotective
function of the PN extract was further evaluated and its ef-
ficacy as a therapeutic agent was experimentally tested on a
rat model of liver cirrhosis induced chemically by thioac-
etamide (TAA) administration. TAA was originally used as
a fungicide to preserve agricultural citrus products, but later
it was determined that it was a potent hepatotoxin and
carcinogen because its thono-sulfur-containing compound
endowed with liver-damaging and carcinogenic activities [9].
On a prolonged exposure, TAA leads to the formation of
hyperplastic nodules, cell adenomas, hepatocarcinomas, and
cirrhosis. TAA-induced cirrhosis in rats has been shown to be
a suitable experimental model of this disease with etiology
and pathology comparable to the one seen in humans
[10].
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This study was performed as a continuum of the pre-
vious works reported by our laboratory Harish and Shiv-
anandappa [7], or other groups Bhattacharjee and Sil [8], to
objectively evaluate the therapeutic role of the PN extract on
liver cirrhosis, we also employed another herbal substance
silymarin with a well-established record of being a hepato-
protectant agent [11]. Silymarin is a purified extract obtained
from the seeds of the plant Silybummarinum and used widely
as a supportive therapy for liver disorders such as cirrhosis,
hepatitis, and fatty acid infiltration due to alcohol and toxic
chemicals [12]. The hepatoprotectant eﬀect achieved with
the PN extract was compared against the benchmark eﬃcacy
obtained from silymarin treatment. In the following, we des-
cribe each of the processes and procedures employed in our
experiments, present results showing the changes in liver
pathology and biochemicals with and without treatment in
groups of experiments and discuss our findings in detail
regarding the merits of the PN extract as a potential treat-
ment agent against liver cirrhosis.
2. Materials and Methods
The study was approved by the institutional Ethics Commit-
tee, University of Malaya, Malaysia, with protocol number
PM/28/08/2010/MAA. Throughout the experiments, we pro-
vided human care to the animals according to the criteria
outlined in the “Guide for the Care and Use of laboratory
Animals” prepared by the National Academy of Sciences and
published by the National Institutes of Health.
Adult male healthy Sprague Dawley rats weighing bet-
ween 190–260 g were acquired from the experimental animal
house in our institute and were maintained on standard
pellet diet and tap water and kept at 25 ± 3◦C temperature,
50–60% humidity, and a 12 h light-dark cycle for at least one
week before starting the experiment.
2.1. Preparation of the Phyllanthus niruri Extract. Fresh
plants of PN were purchased from (Ethno Resources Sdn
Bhd, Selangor Malaysia) and identified by comparison with
the voucher specimen deposited at the Herbarium of Rimba
Ilmu, Institute of Science Biology, University of Malaya,
Kuala Lumpur (voucher number KLU46618). The plant was
dried and grinded into fine powder. Hundred gram of the
powder was soaked in 1000mL of 95% ethanol for 3 days.
Then, the mixture was filtered using filter paper (Whatman
No. 1) and distilled under reduced pressure in a rotating
evaporator (Buchi, Switzerland). The ethanol extract was
then dissolved in 10% Tween 20 and administered orally to
the rats.
2.2. Preparation of Thioacetamide. TAA (Sigma-Aldrich,
Switzerland) was prepared freshly by dissolving in sterile dis-
tilled water (2mL/kg body weight) and stirred well until all
crystals were dissolved. Then, 200mg/kg body weight was
administered intraperitoneally (ip) to the rats thrice weekly
for 8 weeks. The injection protocol above was according to
the recommendation of Alshawsh et al. [2]. Constant expo-
sure to a rat with this amount of TAA induces changes in
its liver pathology from both biochemical andmorphological
aspects comparable to that of human liver cirrhosis [13] and
therefore used very often as a preferred model in experimen-
tal studies of this disease.
2.3. Preparation of Silymarin. Silymarin (International Lab-
oratory, USA) is a reference drug and (5mL/kg body weight)
was dissolved in sterile distilled water for oral administration
to rats in doses of 50mg/kg body weight.
2.4.AcuteToxicityTest. Testswere initially performedto deter-
mine the safety of the PN extract when administered orally,
the acute toxicity test was performed following OECD-423
guidelines [14]. Twenty-four healthy SpragueDawley rats (12
males and 12 females) were randomly assigned equally into 3
groups labeled as vehicle 10% Tween 20 and two large doses
2 g/kg and 5 g/kg of the extract, respectively. Each rat was
made to fast (no food but water) overnight prior to dosing.
Food was withheld for another 3 to 4 hours after the dosing.
The rats were closely observed for 30min and at 2, 4, 24, and
48 h after the dosing to detect if there were any acute signs
of clinical or toxicological symptoms. After 14 days the rats
were sacrificed to measure serum biochemical and (liver and
kidney) histological parameters by following the standard
methods [15].
2.5. Experimental Protocols. Forty male rats were randomly
divided into five groups, each of which with eight rats: Group
1 (control group) rats were administered orally with 10%
Tween 20 (5mL/kg) daily and injected intraperitoneally with
sterile distilled water (2mL/kg) thrice weekly for 8 weeks.
Group 2 (hepatotoxic group) rats were administered orally
with 10% Tween 20 (5mL/kg) and injected intraperitoneally
(ip) with Thioacetamide (TAA) (200mg/kg) thrice weekly
for 8 weeks. The injection protocol above was according to
the recommendation of Alshawsh et al. [2]. Group 3 (refe-
rence drug group) rats were administered orally with sily-
marin (50mg/kg) daily and injected ip with TAA (200mg/
kg) thrice weekly for 8 weeks. Groups 4 and 5 (PN treatment
groups) rats were administered orally with the PN extract
100mg/kg and 200mg/kg daily and injected ip with TAA
(200mg/kg) thrice weekly for 8 weeks [16].
In this regard, the experiment aimed to protect the liver
from further deterioration. Body weights of rats in all groups
were measured weekly. After 8 weeks, each rat was made
to fast for 24 hours after the last treatment and then per-
fused under Ketamine (30mg/kg, 100mg/mL) and Xylazine
(3mg/kg, 100mg/mL) anesthesia.
2.5.1. Postmortem Tissue Analysis. The livers and spleens of
the perfused rats were dissected, washed with normal saline,
blotted with filter papers, weighed, and examined. The liver
and spleen indices were calculated as the percentage of the
body weight. Liver specimens were subsequently fixed in
10% buﬀered formalin and embedded in paraﬃn using auto-
mated tissue processing machine (Leica, Germany). Sections
were sliced at 5 µm thickness and stained with haematoxylin
and eosin (H&E) for histological evaluation.
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Table 1: Eﬀects of 2 g/kg and 5 g/kg PN ethanol extract on liver biochemical parameters.
Groups
ALT
(IU/L)
AST
(IU/L)
ALP
(IU/L)
Total protein
(g/L)
Albumin
(g/L)
Total bilirubin
(µmol/L)
G-glutamyl
transferase
(IU/L)
Tween 20 (10%) 45.00± 5.32 27.00± 4.16 97.67± 13.86 73.00± 2.96 44.17± 2.59 10.17± 2.26 58.17± 9.90
PN extract (2 g/kg) 49.67± 4.60 26.33± 3.22 92.67± 9.76 74.50± 2.31 42.83± 1.97 8.00± 1.06 37.67± 6.82
PN extract (5 g/kg) 45.17± 5.30 28.00± 3.65 78.33± 6.81 74.33± 2.72 42.50± 2.93 9.50± 1.69 55.00± 8.83
Values were expressed as mean ± S.E.M. There are no statistically significant diﬀerences between the measurements in diﬀerent groups. The significant value
was set at P < 0.05.
Table 2: Eﬀects of 2 g/kg and 5 g/kg PN ethanol extract on kidney biochemical parameters.
Groups
Sodium
(mmol/L)
Potassium
(mmol/L)
Chloride
(mmol/L)
CO2
(mmol/L)
Anion gap
(mmol/L)
Urea
(mmol/L)
Creatinine
(µmol/L)
Tween 20 (10%) 141.33± 1.59 4.33± 0.27 102.83± 1.05 26.83± 1.72 14.33± 1.75 4.60± 0.70 37.33± 0.18
PN extract (2 g/kg) 140.00± 1.77 4.37± 0.30 103.17± 1.45 26.33± 1.59 13.00± 1.44 4.57± 0.70 37.60± 0.19
PN extract (5 g/kg) 137.17± 1.14 4.42± 2.39 102.67± 0.99 22.17± 0.60 17.83± 1.45 4.73± 0.67 37.52± 0.11
Values were expressed as mean ± S.E.M. There are no statistically significant diﬀerences between the measurements in diﬀerent groups. The significant value
was set at P < 0.05.
2.5.2. Antioxidant Activity. Hepatic tissues from all livers
were sampled from the same site of the left lobe, but
away from the portal system. One gram of the sampled
tissue was placed in 10mL (10% w/v) of PBS (phosphate
buﬀer solution with pH 7.4), then homogenized and cen-
trifuged at 4000 rpm for 10min at −4◦C. The supernatant
was kept in a −80◦C freezer and assays were performed
according to the instruction manual from the manufacturer.
Commercially available kits (Cayman Chemical Co., USA)
were used to determine the total antioxidant capacity (TAC)
and malondialdehyde (MDA), catalase (CAT), superoxide
dismutase (SOD), and glutathione peroxidase (GPX) con-
tent.
2.5.3. Hepatic Biochemical Parameters. Blood of each rat was
collected and serum was separated for analysis in the Clinical
Diagnostic Laboratory (CDL) at University of Malaya Medi-
cal Center (UMMC) to determine the liver function enzymes
such as alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (ALP), bilirubin,
albumin, total protein (TP), and gamma glutamyl transferase
(GG).
2.6. Quantitative Estimation of Total Phenolic Contents. The
total phenolic content of PN was determined following
the method of Basma et al. [17] with Folin-Ciocalteu
reagent using gallic acid as standard. 10 µL of extract
solution (1mg/mL) was added and followed by 0.5mL
of 1 : 10 Folin-Ciocalteu reagent. The mixture was incu-
bated at room temperature for 5 minutes then 0.35mL of
115mg/mL natrium carbonate (Na2CO3) was added and
mixed thoroughly. The mixture was then placed for 2 hrs
at room temperature. Absorbance readings were taken spec-
trophotometrically at 765 nm. The total phenolic content
was expressed in mg of gallic acid equivalents to gm PN
extract.
2.7. Statistical Analysis. Statistical analysis was evaluated by
using one-way analysis of variance (ANOVA) with posthoc
test using Bonferroni multiple comparisons in the PASW
program (version 18) for Windows (SPSS Inc. Chicago, IL,
USA). The data were reported as the mean ± S.E.M.; a
probability value less 0.05 was considered significant.
3. Results
3.1. Acute Toxicity Tests. There were no mortality in the rats
administered with the doses 2 g/kg and 5 g/kg of the PN
extract. Physically, they appeared normal and no signs of
changes were observed in their skins, furs, eyes, and mucus
membranes and salivations. Tremor, sleep, and behavior pat-
terns were similar to those of the vehicle treated-rats. Their
food intakes were normal and neither diarrhea nor other
digestional problems was noticed. Weight gains in these rats
paralleed to those in the vehicle group. The biochemical mea-
surements reflected that these organs had normal functions,
as supported by the quantitative data in Tables 1 and 2.More-
over, the vehicle group showed no abnormalities or side
eﬀects resulting from 10% Tween 20. These findings pro-
vided suﬃcient evidence to conclude that the orally admin-
istered extract was safe and did not cause extract-related
toxicity.
3.2. PN Treatment Experiment
3.2.1. Body, Liver, and Spleen Weights. The measurements of
the body, liver, and spleen weights of the rats by the end of
the study in all groups were listed in Table 3. The hepatotoxic
rats weighted significantly less, but their livers and spleens
weighted significantly more compared with the control rats.
The rats subjected to the treatment with either silymarin or
the PN extract exhibited gains in the body weight and losses
in the liver and spleen masses, but the amounts were not as
much as those in the control group.
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Table 3: Body, liver, and spleen weights of the rats in diﬀerent groups.
Groups Body wt. (gm) Liver wt. (gm) Liver index (%) Spleen wt. (gm) Spleen index (%)
Control 237.0± 17.24 6.2± 0.49 2.63± 0.13 0.36± 0.02 0.16± 0.02
TAA 195.4± 18.35 9.4± 0.98 4.81± 0.23a 0.51± 0.10 0.25± 0.04
Silymarin 222.0± 12.00 9.2± 0.97 4.10± 0.22 0.53± 0.04 0.24± 0.01
PN 100mg/kg 258.6± 14.02 8.2± 1.02 3.22± 0.41b 0.46± 0.04 0.18± 0.02
PN 200mg/kg 253.4± 16.41 7.8± 0.58 3.18± 0.24c 0.40± 0.04 0.16± 0.01
The data were stated as mean ± S.E.M. Means with diﬀerent superscripts are significantly diﬀerent. aP < 0.05 versus normal control group, bP < 0.05 versus
TAA control group, and cP < .01 versus TAA control group.
Table 4: Eﬀects of TAA, PN, and silymarin on antioxidant enzymes activities.
Groups TAC (mM) CAT (nmol/min/mL) SOD (U/mL) MDA (µM) GPX (nmol/min/mL)
Control 7.83± 1.47 848.3± 2.11 246.6± 4.12 30.10± 9.09 1438.4± 1.4
TAA 4.48± 1.54 964.9± 4.5a 310.3± 10.0a 59.77± 8.41a 1466.1± 2.0
Silymarin 8.37± 0.43b 839.7± 48.3c 280.2± 12.3 30.43± 2.53c 1437.8± 55.9
PN 100mg/kg 6.73± 0.21 898.3± 1.9 293.6± 29.2 37.77± 8.35b 1457.0± 36.1
PN 200mg/kg 6.72± 0.91 854.03± 15.9c 287.8± 5.55 29.10± 8.25c 1451.2± 9.4
The data were stated as mean ± S.D. Means with diﬀerent superscripts are significantly diﬀerent. aP < 0.05 versus normal control group, bP < 0.05 versus
TAA control group, and cP < 0.01 versus TAA control group.
3.2.2. Gross Morphology. As depicted in Figure 1, the control
rats had livers with smooth surfaces. In the hepatotoxic
group, exposure to TAA made the liver attain irregular shape
and at the same time be occupied with uniform formations of
micronodules andmacronodules (whitish granules), some of
which were localized close to the surface. The nodular trans-
formation in liver parenchyma is also a typical characteristic
of human cirrhosis. The treatment with either silymarin or
the PN extract prevented the development of the macro- and
micronodules and made the liver preserve its nearly normal
anatomical shape and appearance in rats. Although based on
visual evaluations, these results clearly demonstrated that the
PN extract eﬀectively prevented the development of the nod-
ules and hence protected the liver from further deterioration
of its structure and function.
3.2.3. Liver Histopathology. Example slides were given in
Figure 2. In the control group, the livers were clear of any
pathological abnormality, and their sections looked normal
with regular cellular architecture. The hepatic cells had
intact cytoplasm, sinusoidal spaces, prominent nucleus, and
nucleolus and central vein. In the hepatotoxic groups, the
histology confirmed liver damage as evidenced by the pre-
sence of inflammation and necrosis in the respective liver
sections. The architecture of the liver parenchyma was dis-
torted by fibrous septa that formed collagen bridges between
the hepatic triads delineating the small and large regenerative
nodules of hepatocytes or necrosis. The nodules were sur-
rounded by a thick fibrous septa which divided the liver into
pseudolobules. There were observations of cytoplasmic vac-
uolization, megalocytosis, bile duct proliferation, hepatocyte
degeneration, necrosis, infiltration of inflammatory cells,
and centrilobular necrosis with portal triaditis, expanded
portal tracts, and collagen deposition. The spindle and
hepatic cells surrounding the central vein proliferated and
various degenerative changes like cloudy swelling, hydropic
degeneration, loss of nucleus and nucleolus, and necrosis
have taken place [18].
The rats in silymarin-treated group exhibited signifi-
cantly lesser pathology as compared to the extensive liver
damage found in the hepatotoxic group. Silymarin admin-
istration prevented the swelling, lymphocytes infiltration,
hepatic necrosis, and fibrous connective tissue proliferation
induced by TAA. Consequently, the liver tissue preserved its
nearly normal hepatic lobular architecture with central veins
and radiating hepatic cords. These results reconfirmed the
protective functions of silymarin against the TAA-induced
liver damage.
The histopathological examination of the liver sections
from the rats treated with the PN extract revealed reduced
degrees of fibrosis, but smaller necrotic zones with nodules
and centrolobular veins still occupied the parenchyma. The
livers had appreciable levels of normal parenchymal architec-
ture with thinner fibrous septa, and lesser amounts of cyto-
plasmic vacuolization, megalocytosis, bile duct proliferation,
and nucleic injury. These results provided microscopic evi-
dence that demonstrated the significant hepatopreservation
function of the PN extract to counterbalance the negative
eﬀects of TAA in the liver tissue.
3.2.4. Antioxidant Activity. Quantitative estimation of total
phenolic contents of PN revealed that this plant enclose
(270± 0.003mg GAE/gm of PN extract) polyphenolic com-
pounds with standard curve equation shown in Figure 3.
Moreover, Table 4 lists the activities of enzymes involved
in the hepatic antioxidant defense system. It is recorded that
SOD, CAT, and GPX enzyme levels were increased in TAA
groups when compared with the control groups and similarly
their levels decreased in silymarin and the PN extract treated
groups. Additionally, the total antioxidant capacity (TAC)
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Figure 1: Images showing the macroscopic appearances of livers from diﬀerent experimental groups. (Control): regular smooth surface.
(Hepatotoxic): iirregular whitish micro- and macronodules and a large area of ductular cholangiocellular proliferation embedded within
fibrosis. (Silymarin): smooth surface. (High dose PN): nearly smooth surface.
values were substantially increased in the treatment groups
in comparison to the TAA group. However, data from Table 4
indicates that the lipid peroxidation values in the livers of the
PN treated rats were lower than those in the TAA group. This
set of data indicates that the PN extract is an antioxidant and
protects the liver through this property.
3.2.5. Hepatic Biochemical Parameters. The activities of alka-
line phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), bilirubin, total protein,
albumin, and gammaglutamyl transferase (GG) were shown
in Table 5. Significant increases in the serum ALP, ALT, AST,
bilirubin, and GG, but substantially lower total protein and
albumin levels were detected in the hepatotoxic rats com-
pared to those in the control group. Silymarin therapy was
eﬀective and restored the activities of these serum biochem-
icals closer to their normal levels. Treatments with the PN
extract at the dose 200mg/kg produced activities similar to
those seen with silymarin. These results demonstrated the
capacity of the PN extract to control the abnormal hepatic
biochemical activities initiated by TAA.
4. Discussion
Liver functions as an endogeneous metabolism center for
nutrients, such as carbohydrates, proteins, and lipids, and
also participates in disposal of waste metabolites. The organ
also handles the metabolization or excretion of exogeneous
drugs and other xenobiotics. In this regard, liver plays a
major role in protecting and detoxifying the body from for-
eign substances [19]. Liver cirrhosis is a major disease asso-
ciated with various pathological processes including progres-
sive fibrosis, portal hypertension and carcinoma [20]. Free
radical generation, mitochondrial dysfunction and depletion
of antioxidants lead to the progression of fibrosis and cirrho-
sis [21]. Thioacetamide is an organic solvent with thiono-
sulfur components have been used widely to induce liver
cirrhosis [22–26]. In the present study, the prolonged admin-
istration of TAA to the rats caused visual and quantifiable
responses, which were recognizable by the alterations in the
body and liver weights, appearance of gross morphology, dis-
tinct stained patterns of histopathology, and levels of serum
molecular markers. All these indications were of cirrhosis
and supported the past reports that TAA contributes to the
development of cirrhosis through multiple mechanisms of
action [27] like the oxidation of its metabolic products
[28, 29], oxidative stress [30, 31], and decreased antioxidant
defenses and lipid peroxidation. During the eight-week-long
study, the hepatotoxic rats lacked in gaining body weight as
compared with the controls (Table 3). Using the same exper-
imental model of cirrhosis, the previous studies reported the
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Table 5: Eﬀects of TAA, PN, and silymarin on hepatic biochemical parameters.
Groups ALT (IU/L) AST (IU/L) ALP (IU/L) T. protein (g/L) Bilirubin (µmol/L) Albumin (g/L) GGT (IU/L)
Control 66.0± 3.63 162.6± 9.35 109.8± 10.85 72.0± 1.16 2.0± 0.00 11.0± 0.32 8.4± 0.40
TAA 165.6± 19.58a 484.8± 103.83a 431.2± 72.94a 58.80± 1.07a 7.4± 1.07a 8.4± 0.22 18.4± 3.5a
Silymarin 63.0± 4.16c 158.0± 16.77c 86.0± 51.45 67.20± 2.73c 1.8± 0.32c 10.8± 0.73 13.3± 0.97
PN 100mg/kg 82.6± 4.10c 282.2± 24.57c 272.4± 17.38c 70.0± 1.00b 5.2± 0.92 10.4± 0.38 15.6± 2.25
PN 200mg/kg 78.2± 6.39c 180.6± 25.86c 140.2± 26.63c 71.25± 0.66c 3.4± 0.37c 10.7± 0.15 11.0± 1.76
All values are expressed as mean± S.E.M.Means with diﬀerent superscripts are significantly diﬀerent. aP < 0.05 versus normal control group, bP < 0.05 versus
TAA control group, and cP < 0.01 versus TAA control group. ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase,
GGT: gamma glutamyl transferase.
Control TAA
Silymarin PN
Figure 2: Histopathology images of the livers from diﬀerent experimental groups. (Control): normal structure and architecture. (TAA):
structural damage, necrosis, and pseudolobules with thick fibrotic septa. (Silymarin): mild inflammation but no fibrotic septa. (PN): partially
preserved hepatocytes and architecture with small areas of mild necrosis.
same and attributed this outcome to the lower levels of nutri-
ent absorption, energy utilization, and metabolic eﬃciency
as the major factors aﬀecting the inability of the rats to gain
weight after being exposed to TAA [2]. Factoring the reduced
body weight into the calculation yielded significantly high
ratios of liver and spleen-to-body weight. The hepatocyte
proliferation is a critical determinant for the survival of liver
from an injury [32]. Based on this, the upregulation of the
hepatocyte activity in response to the exposure to TAA toxi-
city is likely to be the cause of the recorded increase in the
liver and spleen weights.
Ex vivo examinations of the livers from the hepatotoxic
rats exhibited numerous white and yellow-colored nodules
(Figure 1), which closely resembled the human cirrhosis with
hepatocarcinoma in both pathobiological and morpholog-
ical aspects [10]. The agreement between our results and
those of the previous works in several fronts confirmed that
our experimental rat model of cirrhosis was suitable for
testing the eﬃcacy of any applied preclinical therapy with a
clinical translation in focus.
This study showed that liver’s total antioxidant capacity
in vivo (TAC) reduced in the TAA-treated rats when com-
pared to control rats while the PN and silymarin treatments
in turn elevated the levels near to control. On the other hand,
TAA group exhibited higher values of cellular lipid perox-
idation which measured through the malonialdehyde level
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Figure 3: Standard curve of quantitative estimation of total pheno-
lic content in PN extract.
(MDA) than did the control livers. SOD, CAT, and GPX levels
in the liver homogenates of PN-treated rats were found to
be significantly higher than the TAA group. These results are
in agreement with the previous studies which reported that
the reason of PN’s usage in treatment of liver diseases is in
its eﬃcacy in inhibition of reactive oxygen species and lipid
peroxidation [33].
In the hepatotoxic rats, we detected elevated levels of
serum ALT, AST, ALP, and total bilirubin concentrations
(Table 5), which were typically measured for assessing the
liver function. Such enzymatic activities were in line with the
earlier reports [32]. The increase in serum enzymatic activ-
ities is related to hepatic parenchymal damage since ALT is
released from mitochondrial and cytosolic localization from
membranal sites, and cellular rupture allows the enzyme to
escape into the blood [33]. The raised serum liver enzymes
such as ALT, AST, and ALP in intoxicated rats compared to
normal indicates necrosis of hepatocytes that results in the
leakage of transaminase and the elevation of serumALP from
a possible cholestasis and this also can be attributed to the
damage in the histostructural integrity of the hepatocytes
[34].
TAA grossly impairs the erythrocyte plasma membrane
stability, producing a labile membrane which was easier to
lyse. High dose of bilirubin detected in the hepatotoxic rats
was an indication of the increased erythrocyte degenera-
tion rate. The liver excretes the breakdown products of
hemoglobin, particularly bilirubin, whose level is used to
evaluate chemically induced hepatic injury and hence reflect
the necrotic conditions of hepatocytes [33]. The total protein
and albumin levels are depressed in hepatotoxic conditions
due to disturbances in the carbohydrate, protein, lipid
metabolisms or perturbed protein biosynthesis in the cir-
rhotic liver. The marked reduction of the total protein syn-
thesis in the hepatotoxic rats in our experiments was in
agreement with the early observations of decreased riboso-
mal RNA in TAA-treated rats cells. Since the decrease in RNA
occurs in cells where RNA polymerases is activated, defective
intranuclear RNA processing is the most likely explanation
of the observed decrease [35].
Silymarin is a well-established plant-based formulation
and a clinical drug with proven capacity to guard liver from
harmful hepatotoxins. Such pharmacological power was
attributed to silymarin’s inherent constituents with antioxi-
dant, anti-inflammatory, and diuretic properties, as in other
medicinal plants in nature [11]. In addition, silymarin has
the capacity as antilipid peroxidation and induced detoxifi-
cation system, protector of cell against employed glutathione,
reducer of leukotiene formation from unsaturated free acid,
enhancer of protein synthesis, stabilizer of mast cells and
regulator of immune functions. It inhibits cytoP450 detoxi-
fication system and prevents metabolism of toxic compound
such as TAA [36].
In our study, we reconfirmed that silymarin played subs-
tantial role against the progression of cirrhosis induced by
TAA in rats (Figures 1 and 2 and Tables 3, 4, and 5). It signi-
ficantly reduced the liver pathology indicated by the declined
levels of ALT, AST, ALP, bilirubin, and increased albumin and
total protein levels activities as compared to the hepatotoxic
rats. The readings for these biochemicals were the best achie-
vable values and therefore set the baseline for comparisons of
the therapeutic improvements attained with the PN extract.
The treatment of the rats with the ethanol extract from
the plant PN has proven to be a useful strategy against the
pathophysiological and biochemical changes induced by the
hepatotoxin TAA in the rat model of cirrhosis (Figures 1 and
2 and Tables 3, 4, and 5).We however note that the PN extract
reversed the toxicity produced by TAA in a dose dependent
manner, where 200mg/kg was more eﬀective than 100mg/kg
of dose. Nevertheless, in the rats treated with PN, the bodies
weightedmore and livers and spleens weighted less compared
with those of the cirrhotic rats. The treatment ultimately
resulted in decreased liver to body weight ratio, which was
closer to that of the controls (Table 3). Visual evaluation
and histopathological analysis demonstrated that the liver
structure and architecture remained nearly intact and con-
tained lesser fibrosis and lower number of nodules than the
cirrhotic rats (Figure 2). Biochemical analysis indicated that
parameters of interest read closer to the levels measured from
the control rats. The data in Table 5 indicates that the
extract treated the rise of the serum levels of ALT, AST,
ALP, and bilirubin, and the decline in the levels of albumin
and total protein. The reduction seen in the levels of these
enzymes in the treated rats hinted that the PN extract
has stabilized the hepatocytes membranes and interrupted
the release of enzymes from liver into blood. The lowered
bilirubin levels supported this action since it implied more
stable erythrocyte plasma membranes were present in the
treated rats. These findings are consistent with those of
Harish and Shivanandappa [7] who found that aqueous
and methanolic extracts of P. niruri showed inhibition of
membrane lipid peroxidation, scavenging of DPPH (1,1-
diphenyl-2 picrylhydrazyl) radical and inhibition of reactive
oxygen species in vitro. Also pretreatment with PN inhibits
carbon tetrachloride (CCl4) induced formation of lipid
peroxides in the liver of rats in vivo. Moreover Sabir and
Rocha [37] demonstrated the hepatoprotective activity of PN
extract in vivo against paracetamol-induced liver damage.
While Chatterjee and Sil [38] results suggested that beneficial
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eﬀect of the aqueous extract of PN, probably through its
antioxidant property, might control the nimesulide-induced
oxidative stress in rats liver.
Thioacetamide is a well-known liver hepatotoxicant, the
hepatotoxicity results from its metabolic conversion to free
radical products: thioacetamide sulfoxide and thioaceta-
mide-S, S-dioxide which attacks microsomal lipids leading
to their peroxidation, and production of reactive oxygen spe-
cies (ROS), such as the H2O2, super oxide anion O
−
2 and
the hydroxyl radical. ROS aﬀects the antioxidant defense
mechanisms, decreases the activity of SOD, CAT, and GPX
that causes liver injury, cirrhosis development, and hepa-
tocarcinoma [39]. Nevertheless, plant derived polyphenols
were well-known free radical scavengers and eﬀective as anti-
oxidants against lipid peroxyl radicals [40]. Since PN enclo-
sed total phenolic content of 270± 0.003mg GAE/gm of PN
extract, thus, the protective activity of PN may be due to
its polyphenols active ingredients; phyllanthin, hypophyl-
lanthin, phyltetralin, niranthin, nirtetralin, hinokinin, and
isolintetralin that identified to exhibit many biological acti-
vities, such as scavenging of free radicals [6, 41] and inhibit-
ing lipid peroxidation [42], which are TAA’s well-known
mechanisms of action in producing liver injury. The capacity
of the PN extract to regulate the hepatic antioxidant status
or to directly participate in H2O2, super oxide anion O
−
2 , and
the hydroxyl radical scavenging process explains the trends
in the measurements towards restoring the balance in serum
chemicals [43].
5. Conclusions
All the observations made and measurements collected in
this study provided preliminary evidence that the progres-
sion of the liver cirrhosis induced by TAA in rats can be inter-
vened using the PN extract. Specifically, this natural extract
has power to protect the liver by preventing the actions of the
harmful events associated with the TAA toxicity from taking
place. The eﬀects are comparable to those of silymarin and
the capability of the PN extract to preserve the liver’s status
quo of property, structure, and function against toxic expo-
sure is encouraging and warrants further studies exploring
the significance of its pharmacologic potential in treating the
liver cirrhosis by mapping the molecular pathways of action.
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